EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations

Sean M Watson, Edward P Harvey, Novalia Pishesha, Hidde L Ploegh, Timothy A Springer

Journal of Biological Chemistry · 2025-07 · 301 (7) · 110374

DOI: 10.1016/j.jbc.2025.110374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-07. Verfasst von Sean M Watson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Program in Cellular and Molecular Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA; Department of Biologica…. Hauptthemen laut MEDLINE: Glioblastoma, ErbB Receptors, Single-Domain Antibodies, Mutation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, Concept Medical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic mutations in the epidermal growth factor receptor (EGFR) promote tumorigenesis by stabilizing active or pre-active receptor conformations. Most EGFR-driven cancers are characterized by kinase domain mutations that directly activate the receptor. However, brain cancers such as glioblastoma multiforme (GBM) uniquely harbor mutations in the EGFR ectodomain that allosterically activate the kinase domain. Despite significant advances in understanding the physiological and pathogenic roles of EGFR, the conformational characteristics that define ligand-independent EGFR activation in GBM remain poorly understood. In this study, we use naive and post-immune yeast-displayed nanobody libraries to discover four nanobody groups that with benchmark nanobodies define a total of five groups with unique binding signatures and specificities for GBM mutation-stabilized conformational states. Nanobodies in Groups 1 and 2 block ligand, selectively bind the inactive, tethered conformation, and favor wild-type EGFR over GBM-stabilized conformations. In contrast, nanobodies in Groups 4 and 5 do not block ligand, target active or pre-active conformations, and selectively bind GBM-stabilized conformations. Additionally, nanobodies in Group 3 block ligand and appear to be conformation agnostic. We observed domain-specific bias in the nanobodies' selectivity for GBM mutations, suggesting that mutations across different ectodomain regions stabilize distinct conformations. This work advances our understanding of EGFR conformational equilibria in the context of GBM. The observed cooperativity and mutation-dependent binding of nanobodies emphasize their utility in dissecting EGFR activation mechanisms and in developing targeted therapies for EGFR-driven cancers, including GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaErbB ReceptorsSingle-Domain AntibodiesMutationBrain NeoplasmsHumansProtein Conformation

Stichwörter der Autor:innen

epidermal growth factor receptor (EGFR)glioblastomaprotein conformationreceptor tyrosine kinasesingle-domain antibody (sdAb, nanobody)

Substanzen

ErbB ReceptorsSingle-Domain AntibodiesEGFR protein, human

Autor:innen und Institutionen

  • Program in Cellular and Molecular Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, , Bost…
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, , Boston, Massachusetts, USA.
  • Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
  • Program in Cellular and Molecular Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • Concept Medical
  • National Heart Lung and Blood Institute Division of Intramural Research
  • National Science Foundation
  • Harvard Medical School
  • National Science Foundation Graduate Research Fellowship Program

Zitieren

APA

Watson, S. M., Harvey, E. P., Pishesha, N., Ploegh, H. L., & Springer, T. A. (2025). Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations. Journal of Biological Chemistry, 301(7), 110374. https://doi.org/10.1016/j.jbc.2025.110374

Vancouver

Watson SM, Harvey EP, Pishesha N, Ploegh HL, Springer TA. Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations. Journal of Biological Chemistry. 2025;301(7):110374. doi:10.1016/j.jbc.2025.110374

BibTeX
@article{Watson2025,
  author = {Watson, Sean M and Harvey, Edward P and Pishesha, Novalia and Ploegh, Hidde L and Springer, Timothy A},
  title = {Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  volume = {301},
  number = {7},
  pages = {110374},
  doi = {10.1016/j.jbc.2025.110374}
}
Kostenlos starten →